We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Rapidly Detecting Drug-Resistant HepC

Rapidly Detecting Drug-Resistant HepC

Rapidly Detecting Drug-Resistant HepC

Rapidly Detecting Drug-Resistant HepC

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Rapidly Detecting Drug-Resistant HepC "

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

A rapid, sensitive and accurate method to detect drug resistant hepatitis C virus (HCV) mutants has been developed.

HCV is a major cause of chronic liver disease, liver cirrhosis, and hepatocellular carcinoma, affecting up to 180 million people worldwide. HCV often acquires resistance against direct acting antiviral agents. In particular, the presence of the Y93H mutation prior to treatment has been reported as an important predictor of virologic failure. 

Direct sequencing is a commonly used method to detect the Y93H mutation. Unfortunately, it is only capable of detecting viral subpopulations with frequencies of at least 10-20 percent. Next generation sequencing has recently been applied as a more sensitive method to analyze viral mutations, but it is still complex to perform and expensive for widespread clinical use. 

By combining nested PCR and the Invader assay with well-designed primers and probes, researchers have detected the Y93H drug resistant mutation with a high success rate of 98.9 percent among a total of 702 Japanese HCV genotype 1b patients. 

Even in serum samples with low HCV titers, Y93H drug resistant mutation could be successfully detected in more than half of the samples. This new system for detecting mutant strains may provide important pre-treatment information valuable not only for treatment decisions but also for prediction of disease progression in HCV genotype 1b patients.

 “Our assay system also showed a much lower detection limit for Y93H than using direct sequencing, and Y93H frequencies obtained by this method correlated well with those of deep-sequencing analysis,” explained Professor Kazuaki Chayama, the principle investigator of the present study. 

The proportion of the patients with the Y93H mutant strain estimated by this system was 23.6 percent, a rate comparable with that assayed by real-time PCR and ranked between those of deep sequencing and direct sequencing reported in the Japanese population, presumably reflecting the lower detection limit of Y93H. 

This new system attained a high assay success rate and was more sensitive in detecting Y93H than direct sequencing. The evaluation of Y93H strain may provide important information for prediction of disease progression in HCV genotype 1b patients.